A Prospective Non-Interventional Study to Assess Long-term Effectiveness of Zomacton® and Factors Affecting Adherence in Patients With Growth Hormone Deficiency or Growth Retardation Due to Ullrich-Turner Syndrome
Phase of Trial: Phase IV
Latest Information Update: 20 Dec 2018
At a glance
- Drugs Somatrogon (Primary)
- Indications Somatotropin deficiency
- Focus Therapeutic Use
- Acronyms RAZANT
- Sponsors Ferring Pharmaceuticals
- 11 Dec 2018 Status changed from recruiting to discontinued due to Insufficient, delayed recruitment of participants
- 29 May 2018 Status changed from not yet recruiting to recruiting.
- 09 Apr 2018 Planned initiation date changed from 31 Mar 2018 to 31 May 2018.